source
- FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developerThe FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
- BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlookBridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…